New drug combo aims to boost remission in tough blood cancers

NCT ID NCT07294677

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 20, 2026 · Updated 22 times

Summary

This study is for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) that has come back or not responded to treatment. Researchers are adding a drug called capivasertib to a standard chemotherapy regimen (mini-hyperCVD plus venetoclax) to see if it is safe and can help more people achieve remission. The study has three parts: first finding the best dose, then checking safety, and finally comparing the new combo to standard treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Chicago Medicine Comprehensive Cancer Center
RECRUITING

Chicago, Illinois, 60637, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LEUKEMIA LYMPHOMA